ABOS•benzinga•
Acumen Pharmaceuticals Presented Extended Results From Its Validated Research-use Plasma pTau217 Assay To Screen Potential Participants In The Ongoing Phase 2 ALTITUDE-AD Trial Of Sabirnetug
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 2, 2025 by benzinga